Education
About Us
Working with TipRanks
Follow Us
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
SGMT Stock Chart & Stats
$5.67
-$0.58(-10.41%)
At close: 4:00 PM EST
$5.67
-$0.58(-10.41%)
Day’s Range― - ―
52-Week Range$1.73 - $11.41
Previous CloseN/A
Volume1.06M
Average Volume (3M)572.75K
Market Cap
$175.78M
Enterprise Value$143.40M
Total Cash (Recent Filing)$116.69M
Total Debt (Recent Filing)$115.00K
Price to Earnings (P/E)―
Beta2.71
Next Earnings
Mar 30, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding31,001,108
10 Day Avg. Volume777,284
30 Day Avg. Volume572,751
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)0.91
Price to Sales (P/S)0.00
P/FCF Ratio-3.32
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.35
Forecast
1Y Price Target
$25.57Price Target Upside351.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPhase I pharmacokinetic and safety results showed the denifanstat and resmetirom combination was generally well tolerated with no serious adverse events or discontinuations, supporting advancement to a Phase 2 program in advanced liver fibrosis.
Pipeline Breadth And Commercial PotentialDevelopment of multiple FASN inhibitors across acne and liver disease, plus partner activity toward local approval in China, expands commercial pathways and increases upside if efficacy trials succeed.
Strategic Licensing And IPA global license agreement with TAPI for an innovative resmetirom API reduces intellectual property risk around the combo approach and enables work toward a fixed-dose co‑formulation for later‑stage development.
Bears Say
Analyst Report ObjectivityA disclosed potential conflict of interest at the publishing firm may undermine confidence in the objectivity of coverage and contribute to investor uncertainty and stock volatility.
Funding And Dilution RiskCash on hand is described as sufficient for a limited period, suggesting the company may need to pursue additional financing that could dilute existing shareholders or slow program timelines.
Rising Operating ExpensesAnalyst updates incorporated higher near‑term expense estimates based on operational trajectory, indicating increased spending that could further strain available capital.
Sagimet Biosciences, Inc. Class A News
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $1.73 and its highest was $11.41 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $175.78M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Mar 30, 2026 which is in 56 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Nov 13, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.386 by -$0.014.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.42.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 31,001,108 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.386. Following the earnings report the stock price went down -12.245%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sagimet Biosciences, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.57 (351.00% Upside)
$25.57 (351.00% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
39.65%
12-Months-Change
Fundamentals
Return on Equity
-39.78%
Trailing 12-Months
Asset Growth
-26.53%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
SGMT Stock 12 Month Forecast
Average Price Target
$25.57
▲(351.00% Upside)
Technical Analysis
Codexis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
10.06% Insiders
5.84% Mutual Funds
0.03% Other Institutional Investors
79.28% Public Companies and Individual Investors